Coleus Forskohlii (Forskolin) for Blood Pressure Regulation

Research suggests that forskolin, the active compound derived from Coleus forskohlii, may support blood pressure regulation primarily through vasodilatory mechanisms, with multiple studies pointing to its ability to activate adenylate cyclase, reduce systemic vascular resistance, and decrease intrinsic vascular tone in both conductance and resistance vessels. Studies indicate this evidence base includes clinical observations in cardiomyopathy patients, animal studies in hypertensive rats, and at least two randomized controlled trials that collected blood pressure data alongside other outcomes, with reviews consistently characterizing forskolin as having antihypertensive potential. However, the picture is not entirely consistent — one study in mice found cardiovascular benefits without measurable blood pressure changes, and a supplementation study in women noted no clinically significant blood pressure effects, suggesting that the degree of impact may depend on population, dosage form, or baseline cardiovascular status. Additionally, a 2023 RCT examining a multi-ingredient supplement containing forskolin alongside several other compounds found weight and body composition benefits but does not isolate forskolin's contribution to any blood pressure-related outcomes, underscoring a broader limitation in this literature: much of the supporting evidence comes from mechanistic, animal, or small-scale human studies, making it difficult to draw firm conclusions about the magnitude or consistency of any blood pressure-lowering effect in healthy or general adult populations.